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Living Proof is a medical TV drama based on a true story. It 
revolves entirely around the clinical trials and tribulations of 
development of Herceptin®, including the struggles of some 
of the women enrolled in the initial single dosage exploratory 
‘mouse protein study’ and Phase I-III trials. It provides very 
valid medical insights into the potential hardships of medical 
research, funding required for laboratory equipment, and 
recounts a development that proved to be a milestone in the 
treatment of HER-2 (Human epidermal growth factor receptor 
2) positive breast cancer patients. 
Trastuzumab, or as it is better known, Herceptin®, is a 
monoclonal antibody drug used to treat HER2-positive breast 
cancer and HER2-positive metastatic adenocarcinoma of the 
stomach or gastroesophageal junction by targeting the HER-2/
neu receptor.1-5 One of the opening scenes of the movie takes 
place in Dr Dennis Slamon’s laboratory, at the UCLA Medical 
Center in the US, where we are introduced to the protagonist 
and his new assistant. We are also presented to the individual 
lives of different women and their families, who are later 
diagnosed with breast cancer. The movie proceeds to introduce 
the audience to the various phases of drug development. The 
biotechnology manufacturer of Herceptin®, Genentech Inc., 
repeatedly referenced in the film, is seen in the movie to develop 
the drug jointly with Dr Slamon from UCLA. The complete drug 
developmental milestones in the real life story are somewhat 
more comprehensive, and also included other named scientists 
as well, responsible for contributing in various ways to the final 
breakthrough.  
 In parallel, we see one of the patients, diagnosed with 
breast cancer, being presented with the standard options of 
mastectomy, chemotherapy and radiation, which is what 
had been previously offered to her mother. Dr Slamon faced 
numerous challenges throughout the course of the research 
studies, including initial funding issues as well as personal 
hardships. In the Phase I trial, cisplatin was used in combination 
with Herceptin®. Nicole, who had stage 4 cancer was the first 
patient to originally receive the drug during, what is called in 
the movie, the initial exploratory ‘mouse protein study’. This 
involved a single dose to test for tolerance in humans. However, 
she did not meet the eligibility requirements defined by the 
protocols for Phase I, and was hence not included in spite of the 
efforts by her relatives. 
In the movie we see that the supraclavicular lump of a 
patient, enrolled in Phase 1, noticeably decreases in size. On the 
other hand, one of the patients passes away due to her advanced 
cancer. These situations proved to be an emotional roller coaster 
for the cohort. Not all Phase I patients moved forward to Phase 
II, given the stringent Food and Drug Administration (FDA) 
standards for inclusion. During Phase III trials, the National 
Breast Cancer Coalition advocates were involved to allow 
compassionate access to the drug for the women who do not 
qualify for the trial. Towards the end of the movie, during the 
Revlon Run/Walk for women, Dr Slamon meets the relatives of 
some patients. The movie ends with the approval of Herceptin® 
by the FDA, which happened in 1998. 
Although not shown in the movie, but directly related to the 
chemical pathology field of the author, a trastuzumab assay has 
later also been developed for the bioanalytical quantification of 
trastuzumab levels in blood.6-7  
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Help Poppy by prescribing Seretide
Seretide is the only ICS/LABA proven to achieve
guideline-deﬁ ned asthma control in children2
Safety Information
Very common side effects: Headache and nasopharyngitis. 
Common side effects: Candidiasis of mouth and throat, pneumonia, bronchitis, hypokalaemia and hoarseness/dysphonia
Special warnings and precautions for use: Systemic effects may occur with any inhaled corticosteroid, particularly at high doses 
prescribed for long periods. These effects are much less likely to occur than with oral corticosteroids. 
It is important that patients are reviewed regularly and the dose of inhaled corticosteroid is reduced to the lowest dose at which effective 
control of asthma is maintained. Monitor height of children on prolonged inhaled steroid therapy.
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Seretide™ (salmeterol xinafoate and fluticasone propionate) 
Kindly refer to full Summary of Product Characteristics (SPC) before prescribing.
Abridged prescribing information. Presentations: For Malta and Gibraltar: Seretide Diskus – Each dose 
provides 50 microgram salmeterol xinafoate and 100 microgram, 250 microgram or 500 microgram respectively 
of fluticasone propionate. Seretide 50 Evohaler - Each dose provides 25 microgram salmeterol xinafoate and 
50 microgram of fluticasone propionate. For Gibraltar only: Seretide 125, 250 Evohaler: Each dose provides 25 microgram 
salmeterol xinafoate and 125 microgram or 250 microgram of fluticasone propionate. Therapeutic Indications: 
For Malta and Gibraltar: Seretide Diskus and Evohaler: is indicated in the regular treatment of asthma where use of 
a combination (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate. Seretide Diskus is indicated for 
the symptomatic treatment of patients with COPD with a FEV1<60% predicted normal (pre-bronchodilator) and a 
history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy. Seretide 
50 Evohaler is used in patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled 
short acting beta-2-agonist or patients already adequately controlled on both inhaled corticosteroid and long-
acting beta-2-agonist. For Gibraltar only: Seretide 125, 250 Evohaler: is indicated in the regular treatment of asthma 
where use of a combination (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate. Used in patients 
not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short acting beta-2-agonist or 
patients already adequately controlled on both inhaled corticosteroid and long-acting beta-2-agonist. Dosage and 
administration: Seretide is for inhalation use only. Seretide Diskus: Asthma – Adults and adolescents 12 years 
and over: one puff twice daily of Seretide 100 or Seretide 250 or Seretide 500 (each containing 50 mcg of salmeterol 
xinafoate and 100 mcg, 250 mcg or 500 mcg respectively of fluticasone propionate). Patients should be given the 
strength of Seretide containing the appropriate, lowest fluticasone propionate dosage for the severity of their 
disease. A short term trial of Seretide may be considered as initial maintenance therapy in adults or adolescents 
with moderate persistent asthma (defined as patients with daily symptoms, daily rescue use and moderate to severe 
airflow limitation) for whom rapid control of asthma is essential. In these cases, the recommended initial dose is 
one inhalation of 50 micrograms salmeterol and 100 micrograms fluticasone propionate twice daily. Once control of 
asthma is attained treatment should be reviewed and consideration given as to whether patients should be stepped 
down to an inhaled corticosteroid alone. Regular review of patients as treatment is stepped down is important. 
Seretide is not intended for the initial management of mild asthma. Seretide 50/100 micrograms strength is not 
appropriate in adults and children with severe asthma. Children 4-11 years: Seretide 100 Diskus (50 mcg salmeterol 
and 100 mcg fluticasone propionate) – one puff twice daily. Seretide Diskus: COPD: Seretide 500 Diskus (50 mcg 
of salmeterol xinafoate and 500 mcg fluticasone propionate) – one puff twice daily. Seretide 50 Evohaler: Adults 
and children 4 years and older: Two inhalations twice daily. For Gibraltar only: Seretide 125, 250 Evohaler: Adults 
and adolescents 12 years and older: Two inhalations twice daily. Contra-indications: Hypersensitivity. Warnings 
and Precautions: Seretide should not be used to treat acute asthma symptoms for which a fast- and short-acting 
bronchodilator is required. Patients should not be initiated on Seretide during an exacerbation, or if they have 
significantly worsening or acutely deteriorating asthma. Serious asthma-related events and exacerbations can occur 
during Seretide therapy; sudden and progressive deterioration in control or increased use of bronchodilator therapy 
warrants urgent medical assessment especially in patients of African-American origin (SMART). As with all inhaled 
medication containing corticosteroids, Seretide should be administered with caution in patients with pulmonary 
tuberculosis, severe cardiovascular disorders, including heart rhythm abnormalities, diabetes mellitus, untreated 
hypokalaemia/patients predisposed to hypokalaemia or thyrotoxicosis. In case of paradoxical bronchospasm 
discontinue Seretide, assess patient and give alternative therapy if necessary. Systemic effects may occur with any 
inhaled corticosteroid, particularly at high doses prescribed for long periods, but are less likely than with oral 
steroids. It is important, therefore, that the patient is reviewed regularly and the dose of inhaled corticosteroid is 
reduced to the lowest dose at which effective control of asthma is maintained. Prolonged treatment of patients 
with high doses of inhaled corticosteroids may result in adrenal suppression and acute adrenal crises. Rarely, a range 
of psychological or behavioural effects such as psychomotor hyperactivity, sleep disorders, anxiety, depression or 
aggression (particularly in children) may develop on prolonged use. Monitor height of children on prolonged inhaled 
steroid therapy. Transfer from oral steroids: Special care needed. Monitor adrenal function. Consider appropriate 
steroid therapy during periods of stress or elective surgery. Ritonavir can greatly increase the concentration of 
fluticasone propionate in plasma, therefore avoid concomitant use. There is also an increased risk of systemic side 
effects with other potent CYP3A inhibitors. There was an increased reporting of lower respiratory tract infections 
(particularly pneumonia and bronchitis) in the TORCH study in patients with COPD receiving Seretide compared 
with placebo; older patients, patients with a lower body mass index (<25kg/m2) and patients with very severe 
disease (FEV1<30% predicted) were at greatest risk of developing pneumonia regardless of treatment. Concomitant 
use of systemic ketoconazole significantly increases systemic exposure to salmeterol. This may lead to an increase 
in the incidence of systemic effects (e.g. prolongation in the QTc interval and palpitations). Concomitant treatment 
with ketoconazole or other potent CYP3A4 inhibitors should therefore be avoided unless the benefits outweigh the 
potentially increased risk of systemic side effects of salmeterol treatment. Drug Interactions: Avoid beta-blockers. 
Concomitant use with other beta-adrenergic containing drugs can have a potentially additive effect. Potent CYP3A4 
inhibitors: Co-administration of ketoconazole (400 mg orally once daily) and salmeterol (50 mcg inhaled twice daily) 
resulted in a significant increase in plasma salmeterol exposure which may lead to an increase in the incidence of 
other systemic effects of salmeterol treatment (e.g. prolongation of QTc interval and palpitations) compared with 
salmeterol or ketoconazole treatment alone. The concomitant administration of ketoconazole should be avoided, 
unless the benefits outweigh the potentially increased risk of systemic side effects of salmeterol treatment. There 
is likely to be a similar risk of interaction with other potent CYP3A4 inhibitors (e.g. itraconazole, telithromycin, 
ritonavir). Pregnancy and Lactation: Experience limited. Balance risks against benefits. Undesirable effects: 
Very Common/Common - candidiasis of mouth and throat, pneumonia, bronchitis, hypokalaemia, headache, hoarseness/
dysphonia, throat irritation (uncommon with Seretide 50 Evohaler), nasopharyngitis, sinusitis, contusions, traumatic 
fractures, arthralgia and myalgia, muscle cramps (uncommon with Seretide 50 Evohaler). See SPC for information 
on all adverse events. Overdose: due to Salmeterol: tremor, headache, tachycardia; due to Fluticasone propionate: 
temporary adrenal suppression. 
MA Holder (Malta): GlaxoSmithKline (Ireland) Ltd. Trading as: Allen & Hanburys Ltd. MA Numbers (Malta): 
Seretide Diskus: MA 192/00901-3; Seretide 50 Evohaler: AA 192/00904. Legal category: POM. Not all pack sizes may 
be marketed. Date of revision of text: August 2013. 
In order to ensure that this product information reflects the most up-to-date clinical and 
post-marketing surveillance data, please always refer to the latest Summary of Product 
Characteristics which is available from GlaxoSmithKline (Malta) Ltd (Tel: +356 21238131) 
REPORTING ADVERSE EVENTS (AEs): 
If you become aware of any AEs, medication errors and/or use during pregnancy in association 
with GSK products, please report the event promptly to: GSK (Malta) Limited, 1, De la Cruz Avenue, 
Qormi QRM 2458, Malta (Tel: +356 21238131) or e-mail: mt.info@gsk.com
Malta: any suspected AEs and medication errors can also be reported via the national Adverse 
Drug Reactions (ADRs) reporting system: 
Report forms can be downloaded from www.medicinesauthority.gov.mt/adrportal and posted to the Malta 
Medicines Authority, Post-licensing Directorate, 203, Level 3, Rue D’Argens, Gżira GŻR 1368, MALTA, or sent 
by email to postlicensing.medicinesauthority@gov.mt 
Gibraltar: any suspected AEs and medication errors can also be reported via the UK regulatory 
authority (MHRA): https://yellowcard.mhra.gov.uk/
Poppy is 50% less 
likely to wake at night 
when using Seretide 
compared to baseline2
59% of  children wake at
night due to their asthma1
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